Kornimate/medical-research-clean huggingface dataset:
effectiveness of family-based versus individual psychotherapy in treating adolescents with anorexia nervosa

Conditions: Eating Disorders

Summary: this study will compare the effectiveness of family-based therapy versus individual psychotherapy for the treatment of adolescent anorexia nervosa.

in adolescents, anorexia nervosa severely affects physical, emotional, and social development. despite the seriousness and prevalence of adolescent anorexia nervosa, few studies have focused on the effectiveness of various types of psychotherapy treatment. family-based therapy may be an effective approach to treating adolescent anorexia nervosa. this study will compare the effectiveness of family-based therapy versus ego-oriented individual psychotherapy for the treatment of adolescent anorexia nervosa. simultaneously, it will examine potential predictors, mediators, and moderators of weight gain, psychological concerns about weight and shape, and changes in family functioning. participants in this open-label study will be randomly assigned to receive one of two types of therapy: family-based therapy or ego-oriented individual psychotherapy. both types of therapy will be given for a total of 24 hours over the course of 12 months. physical and psychological assessments will be completed during study visits at baseline, immediately post-treatment, six months post-treatment, and one year post-treatment. amount of weight gain will be evaluated, along with changes in weight and body shape concerns, as measured by the eating disorder examination.

Eligibility criteria:
inclusion criteria: * meets dsm-iv criteria for anorexia nervosa * lives with at least one parent who is willing to participate * medically stable * adequate transportation to clinic * proficient at speaking, reading, and writing english exclusion criteria: * currently undergoing treatment or taking medication that may affect eating or weight

Keywords: anorexia nervosa adolescents family therapy individual therapy
comparative urine proteomic studies of overactive bladder in humans

Conditions: Overactive Bladder

Summary: this study is being done to evaluate the use of a new technology (urine proteomics) - the study of proteins in the urine to identify urine markers of overactive bladder (oab) from a simple voided urine specimen.

the objectives of the study are: 1. to improve the diagnosis of overactive bladder using a non-invasive technology (urine proteomics) and 2. to study how potential urine biomarkers changes with overactive bladder symptoms after patients have been treated with fesoterodine, an fda approved drug for the treatment of overactive bladder.

Eligibility criteria:
inclusion criteria: for healthy volunteers the inclusion criteria are: 1. females ≥ 18 years old 2. not experiencing overactive bladder symptoms 3. not experiencing frequency or urgency for overactive bladder patients the inclusion criteria are 1. females ≥ 18 years old 2. overactive bladder symptoms for ≥ 3 months before screening ) recurrent urinary tract infections (utis) \> 3/year exclusion criteria: for healthy volunteers the exclusion criteria are: 1. overactive bladder symptoms, such as frequency and urgency 2. intermittent/unstable use of bladder medications 3. pregnant women or women unwilling to use contraceptives 4. neurological conditions: stroke, multiple sclerosis (ms), parkinson's, spinal cord injury 5. significant pelvic organ prolapsed (grade 3 or above based on physical exam) 6. lower urinary tract surgery within past 6 months 7. known history of ic or pain associated with oab 8. urinary retention requiring catheterization, indwelling catheter of self-cath 9. recurrent utis \> 3/year for overactive bladder patients the exclusion criteria are: 1. contraindications to fesoterodine use such as hypersensitivity, gi and urinary retention, and glaucoma 2. intermittent/unstable use of bladder medications 3. pregnant women or women unwilling to use contraceptives 4. neurological conditions: stroke, ms, parkinson's, spinal cord injury 5. significant pelvic organ prolapsed (grade 3 or above based on physical exam) 6. lower urinary tract surgery within past 6 months 7. known history of interstitial cystitis (ic) or pain associated with oab 8. urinary retention requiring catheterization, indwelling catheter of self-cath 9. recurrent urinary tract infections (utis) \> 3/year deferral criteria: treatment with oab medications within 2 weeks before baseline visit. if patient is currently on oab medications the patient will be asked to stop oab medication for 2 weeks and return for baseline visit.

Keywords: urine proteomics overactive bladder
comparison of the efficacy and safety of continuous and single-dose intravesical epirubicin instillation

Conditions: Bladder Cancer; Epirubicin Adverse Reaction; Superficial Bladder Cancer; Tumor Recurrence

Summary: in this study, the local and systemic side effects, tumor recurrens and progression rates of single or continuous epirubicin instillation during the early postoperative period were investigated in low and intermediate risk non-muscle-invasive bladder cancer.

bladder cancer (bc) is the seventh most commonly diagnosed cancer in the male population worldwide, while it drops to tenth when both genders are considered. worldwide, the bc age-standardised mortality rate (per 100,000 person/years) was 3.3 for men vs. 0.86 for women.it is more common, especially in developed countries. nmibc are divided into four groups as low-medium-high and very high risk according to eortc (european organization for research and treatment of cancer). epirubicin is an anthracycline drug used for chemotherapy. immediate single instillation of epirubicin has been shown to act by destroying circulating tumour cells after turb(transurethral resection of a bladder tumor), and by an ablative effect on residual tumour cells at the resection site and on small overlooked tumours.european association of urology guidelines on bladder cancer advocates single immediate postoperative intravesical chemotherapy. early single-dose instillation of epirubicin immediately after transurethral resection was shown to improve recurrence rates in low and intermediate risk groups. immediate single instillation of epirubicin into the bladder can induce an array of irritative voiding symptoms including dysuria, frequency, urgency, suprapubic discomfort, hematuria and pelvic pain. in some cases, patients cannot tolerate these symptoms and may necessitate removal of chemotherapeutic agent for alleviation. incomplete instillation leads to an increase in recurrence and progression rates. in this study, continuous infusion of epirubicin into the bladder and instillation of a single dose epirubicin will be evaluated in terms of side effects, tumor recurrence and progression rates.

Eligibility criteria:
inclusion criteria: * low and intermediate risk nmibc exclusion criteria: * high risk nmibc * patients who received intravesical bcg * postoperative gross hematuria * bladder perforation * pregnancy * urinary tract infection * epirubicin allergy

Keywords: non-muscle invasive bladder cancer epirubicin intravesical chemotherapy
role of the ans dysregulation in the persistence of fatigue in rheumatoid arthritis patients treated with anti-tnf

Conditions: Rheumatoid Arthritis

Summary: despite the large therapeutic arsenal available since one decade allowing a strong reduction of inflammation process, rheumatoid arthritis (ra) patients claimed pain, fatigue, sleep problems and other quality of life outcomes. fatigue reduction during tnf blockers therapy is lower than the strong reduction in ra disease activity. furthermore, ra patients have higher prevalence of non-inflammatory pain than general population. fatigue is a real major problem due to 50% of patients considered it as severe. this dissociation between disease activity and fatigue level suggests that fatigue is multifactorial. no consistent explanations for fatigue are currently available.


Eligibility criteria:
inclusion criteria : * ra diagnosis according to acr/eular 2010 * ra with low disease activity according to das28 \< 3.2 * written consent obtained exclusion criteria : * other diagnosis than ra * depression known * hypertension treated or not, * diseases interfering with ans analysis: cardiac arrhythmia, beta-blocker therapy, * pregnant or breastfeeding women, * inability to go two consecutive days at the north hospital for the delivery and return of the vista02 device

Keywords: rheumatoid arthritis sympathetic nervous system sna fatigue
sequential and hybrid therapies for h pylori infection

Conditions: Helicobacter Pylori Infection

Summary: primary: to evaluate efficacy of 14 day 2-phase sequential therapy given in two forms. one in which the first component consists of a proton pump inhibitor and amoxicillin given for 7 days followed by the ppi, clarithromycin and metronidazole for 7 days. the alternate will be similar with the exception that the amoxicillin will be continued throughout the 14 days. the secondary endpoint is to evaluate the effectiveness of therapy in relation to antibiotic resistance.

the purpose of this study is to test whether the 14-day sequential therapy ( esomeprazole plus amoxicillin dual therapy for 7 days followed by triple therapy with esomeprazole, clarithromycin, and metronidazole for 7 days) or 14-day hybird therapy (esomeprazole plus amoxicillin dual therapy for 7 days followed by quadruple therapy with esomeprazole, amoxicillin, clarithromycin, and metronidazole for 7 days) can achieve an eradication rate equal to or more than 95%. a total of 240 subjects will be asked to participate in this study. h. pylori-infected patients are randomized to either a 14-day sequential therapy (esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days) or a hybrid therapy (esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days). eradication efficacy is assessed by a follow-up endoscopy with rapid urease test and histological examination eight weeks after the end of anti-h. pylori therapy. the eradication rates of the two study groups will be compared. a successful regimen is defined as a regimen achieving an eradication rate equal to or more than 95%.

Eligibility criteria:
inclusion criteria: * consecutive h. pylori-infected outpatients, at least 18 years of age, with endoscopically proven peptic ulcer diseases or gastritis exclusion criteria: * previous h. pylori-eradication therapy * ingestion of antibiotics, bismuth, or ppis within the prior 4 weeks * patients with allergic history to the medications used * patients with previous gastric surgery * the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia) * pregnant women.

Keywords: helicobacter pylori infection
safety study of autologous cultured adipose -derived stem cells for the fecal incontinence

Conditions: Fecal Incontinence

Summary: fecal incontinence affects 18.4% adults in the community and greatly impacts quality of life. there's a problem like inconvenience, pain or allergic response in many therapeutic methods such as a surgical operation or material injection. ant-sm is autologous adipose-derived stem cell, and so, expect of no immune responses. in this study, patients are given injection of ant-am in anal sphincter and followed for 4 weeks to test the safety.


Eligibility criteria:
inclusion criteria: * older than 18 years * wexner's fecal incontinence score \> or egal 5 * patient who has fecal incontinence for more than 6 months * continuity of anal sphincter at endorectal ultrasound and abnormality of anal function at anorectal manometry * negative for urine beta-hcg for woman of childbearing age * agreement to participate, with signed informed-consent exclusion criteria: * anorectal surgery within the last 6 months prior to the study * patient who is allergy to bovine-derived materials and an anesthetic * patients with a diagnosis of auto immune disease * diagnosis of hbv, hcv, hiv and other infectious disease * patients with a diagnosis of active tuberculosis * patient is pregnant or breast-feeding * women within 6 months post partum * patient who is unwilling to use an "effective" method of contraception during the study * patients with a diagnosis of inflammatory bowel disease * patient who has a clinically relevant history of abuse of alcohol or drugs * insufficient adipose tissue for manufacturing of ant-sm * patient whom investigator consider is not suitable in this study * patients have history of surgery for malignant cancer in the past 5 years * patient who has to undergo ano-rectal surgery * patient who has a history of artificial anal sphincter surgery * patient who has taken cytotoxic drugs within the last 30 days * patient whom investigator consider is not suitable in this study reasons for severe ano-rectal disease, severe constipation, fistula, rectal prolapsed or neurological diseases (spinal cord injury, multiple sclerosis, parkinson's disease)
a clinical trial of csl's 2009 h1n1 influenza vaccine (csl425) in healthy adults

Conditions: Influenza Caused by the Novel Influenza A (H1N1) Virus

Summary: the purpose of the study is to determine whether csl425 is a safe and effective vaccine for eliciting an immune response to h1n1 influenza in healthy adults.


Eligibility criteria:
inclusion criteria: * male or female aged \>= 18 to \< 65 years at the time of providing informed consent. exclusion criteria: * known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, thiomersal, neomycin, polymyxin, or any components of the study vaccine.
mecapegfilgrastim prevents neutropenia and radiation esophagitis

Conditions: Small Cell Lung Cancer

Summary: evaluation of the efficacy and safety of mecapegfilgrastim for the prevention of neutropenia and radiation esophagitis after hyperfractionation in patients with limited-stage small cell lung cancer


Eligibility criteria:
inclusion criteria: * patients with limited small cell lung cancer diagnosed by histopathology; * ecog 0-1 points; * weight ≥ 45 kg; * age 18-75 years old; * it is expected that at least 2 cycles of ep chemotherapy will be completed as planned; once thiophene penicillin is used, chemotherapy should not be re-dosed within 12 days. * bone marrow hematopoietic function is normal, no bleeding tendency (inr\<1.5); * laboratory tests are subject to: (1) blood routine examination: hb≥90g/l; wbc≥4.0×109/ l; anc≥2.0×109/l; plt≥100×109/l. (2) liver function, biochemical examination: alt and ast≤1.5×uln; tbil≤1.5×uln; serum creatinine≤1.5×uln. * according to the researcher's judgment, the test plan can be observed; * volunteer to participate in this clinical trial, understand the research process and be able to sign informed consent in writing. exclusion criteria: * there are currently uncontrolled infections or systemic antibiotics within 72 hours of receiving chemotherapy; * any abnormal bone marrow hyperplasia and other hematopoietic dysfunction; * patients who have received bone marrow or hematopoietic stem cell transplantation within the past 3 months; * patients with previous malignant tumors that have not been cured or have brain metastases; * liver function tests total bilirubin (tbil), alanine aminotransferase (alt), and aspartate aminotransferase (ast) are \>2.5 times the upper limit of normal; if due to liver metastasis, the above indicators are \>5 times the upper limit of normal; * renal function test: serum creatinine (cr) \> 1.5 times the upper limit of normal; * those who are allergic to this product; * suffering from mental or neurological disorders that cannot be matched; * female patients during pregnancy or lactation; women of childbearing age who refuse to receive contraception; * the investigator believes that it is not suitable for inclusion.

Keywords: small cell lung cancer hhpg-19k
opioid free anaesthesia in oncologic gynaecological surgery: is there any benefit?

Conditions: Cervix Cancer; Endometrial Cancer; Ovarian Cancer; Breast Cancer

Summary: opioid free anesthesia (ofa) is a multimodal anesthesia and emerging technique that spares the use of opioids and involve other adjuvant anesthetics, which have demonstrated in vitro influence on immunologic and inflammatory response, as well as in metastatic progression. for these reasons we believe that ofa may positively influence in oncologic patients postoperative recovery and in its disease progression.

after local ethics committee approval, consecutive consenting patients scheduled for major gynecologic oncologic surgery were included between february 2019 and january 2020 in this observational retrospective study. we compared ofa to standard technique used in our institution and assessed its effect on postoperative systemic inflammatory response (sirs), hospital stay, postoperative complications in the following 2 months, cancer progression and mortality 6 months and 12 months after surgery. ofa protocol consisted of a total intravenous anaesthesia of propofol, a dexmedetomidine infusion of 0,8-1,0 mcg/kg/h, together with 0,2-0,3 mg/kg ketamine and lidocaine 1,5 mg/kg in the first hour of surgery. the standard anaesthetic protocol included opioids (fentanyl 2mcg/kg at induction, and remifentanyl infusion 0,1-0,2 mcg/kg/min) and volatile agents (sevoflurane or desflurane). patients in both groups received a regional block when possible, dexamethasone 8 mg at induction and paracetamol 1g plus dexketoprofen 50mg at the end of surgery. continuous variables were compared using unpaired t-test (or mann-whitney u test) and categorical variables by chi-square test. statistical significance was set at p \< 0.05

Eligibility criteria:
inclusion criteria: * patients who had major surgery for gynecologic cancers (cervix, endometrial, ovarian, vaginal, vulvar and breast cancer) under ofa and balanced anesthesia with opioids, both combined with regional anesthesia. exclusion criteria: * patients who had major surgery for gynecologic cancers (cervix, endometrial, ovarian, vaginal, vulvar and breast cancer) under ofa and balanced anesthesia with opioids, but had later surgery with a different to previous anesthesia technique. * patients who had no later follow up during 12 months in the same hospital, so we cannot register recurrence.

Keywords: opioid opioid free anesthesia sirs (systemic inflammatory response) postoperative infection
the effect of video-based testimonials about psychotherapy on treatment expectations and a short online intervention

Conditions: Health Care Utilization

Summary: research has shown that treatment expectations play a major role in the course of mental disorders and that positive expectations have a beneficial impact on treatment outcomes. expectations can develop in different ways and an emerging body of research shows that social learning plays a significant role in this process. to date, most studies have investigated the impact of social learning on treatment expectations in the context of pain relief. little is known about the impact of social learning in the psychotherapeutic treatment of depression. therefore, this study investigates whether treatment expectations about depression therapy and treatment effects of a short online intervention can be modulated via social learning, i.e., showing positive treatment testimonials.


Eligibility criteria:
inclusion criteria: * at least 18 years old * be able understand german (at least b1 level) * have access to a computer device with internet access exclusion criteria: * age below 18 years old * non correctable hearing or visual impairment * diagnosis of borderline-personality disorder * diagnosis of post-traumatic-stress-disorder * self-reported suicidality

Keywords: treatment expectations social learning psychotherapy depression testimonials
ls301-it in partial mastectomy and sentinel lymph node biopsy (slnb) for dcis or stage i-ii primary invasive breast cancer

Conditions: Breast Cancer; DCIS; Invasive Duct Carcinoma of Breast

Summary: the aim of this phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (pk) of a single dose of ls301-it, a novel fluorescence imaging agent developed by integro theranostics (it), administered by intravenous (iv) injection in female patients undergoing partial mastectomy for dcis (whether or not undergoing planned slnb) or stage i-ii primary invasive breast cancer undergoing slnb. safety is the primary objective of this study, followed by efficacy that will be assessed from fluorescence imaging observations and data.

this is a phase 1b/phase 2, open-label study to investigate the use of ls301-it (investigational medicinal product \[imp\]), a fluorescence imaging agent used for visualization of tumor margins and slns in female patients with dcis or stage i-ii, primary invasive carcinoma of the breast, for which the patient's primary surgical treatment is partial mastectomy. eligible patients will be enrolled into either: * phase 1b (period 1): dose finding (escalation/de-escalation), and dose timing adjustment; * phase 2a (period 2): expanded sample size based on acceptable dosing regimen, that being the dose level(s) and time interval between ls301-it injection and surgery, determined in period 1; or * period 2b (period 3): allow surgeon to make additional surgical decisions based on fluorescence imaging findings during surgery (period 3 will not be opened until results are available from periods 1 and 2 and further fda consultation is obtained).

Eligibility criteria:
inclusion criteria: * dcis (whether or not undergoing planned slnb) or patients with stage i-ii, primary invasive carcinoma of the breast undergoing slnb for which the patient's primary surgical treatment is single breast partial mastectomy. * ecog performance status of 0 to 2 exclusion criteria: * contraindications for surgery. * simultaneous bilateral lumpectomies and bilateral partial mastectomies. * history of drug-related anaphylactic reactions, including those attributed to indocyanine green (icg) or other agents used in the study * prior chemotherapy, endocrine therapy, or biologic therapy for current clinically or biopsy proven breast cancer for period 1. * open surgery in the ipsilateral breast within a period of 1 year before administration of ls301-it. * history of radiation therapy to the chest. * the lymphatic imaging agent icg cannot be used prior to the partial mastectomy and slnb procedures on the day of surgery.
neuroimaging study

Conditions: Cognitive Impairment

Summary: the researchers are trying to gather information and learn more about imaging tests in racially different people who are cognitively normal or have dementia.


Eligibility criteria:
inclusion criteria: * male or female african americans 30 years of age or older * subjects who have completed or are scheduled to undergo the neurological evaluation procedures described below. exclusion criteria: * subjects unable to lie down without moving for 20 minutes. * women who are pregnant or cannot stop breast feeding for 24 hours. * claustrophobic patients unable to tolerate the scans. * subjects with a prolonged qt interval (as demonstrated by ecg test) cannot participate in the tau-pet scans. * standard safety exclusionary criteria for mri such as metallic foreign bodies, pacemaker, etc, since the quantitative pet data analysis is based on anatomic criteria that are established uniquely for each subject by registration to his/her mri.

Keywords: african americans neurological exam dementia alzheimer's disease